GALT

SEC source: 0001133416-24-000072 · form4.xml · derivative · entry 3

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024.

F3 · derivative.exercise_price: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024.

F3 · derivative.exercise_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024.

F3 · derivative.expiration_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024.

SEC source: 0001133416-24-000072 · form4.xml · nonDerivative · entry 2

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,346

F2 · shares: Shares of common stock sold pursuant to previously disclosed 10b5-1 plan.

F4 · price: Multiple transactions ranging from $0.92 to $0.85 with an average of $0.8821.

SEC source: 0001133416-24-000072 · form4.xml · nonDerivative · entry 1

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock units.

SEC source: 0001133416-24-000070 · form4.xml · derivative · entry 4

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 56,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024.

F3 · derivative.exercise_price: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024.

F3 · derivative.exercise_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024.

F3 · derivative.expiration_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024.

SEC source: 0001133416-24-000070 · form4.xml · nonDerivative · entry 2

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 897,012

F2 · shares: Shares of common stock sold pursuant to previously disclosed 10b5-1 plan.

F5 · price: Multiple transactions ranging from $0.92 to $0.85 with an average of $0.8859.

SEC source: 0001133416-24-000070 · form4.xml · nonDerivative · entry 1

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 953,012

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock units.

SEC source: 0001133416-24-000068 · form4.xml · derivative · entry 3

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024.

F3 · derivative.exercise_price: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024.

F3 · derivative.exercise_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024.

F3 · derivative.expiration_date: Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024.

SEC source: 0001133416-24-000068 · form4.xml · nonDerivative · entry 2

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,614

F2 · shares: Shares of common stock sold pursuant to previously disclosed 10b5-1 plan.

F4 · price: Multiple transactions ranging from $0.92 t0 $0.85 with an average price of $0.8873.

SEC source: 0001133416-24-000068 · form4.xml · nonDerivative · entry 1

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,614

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock units.

SEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 8

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 741,416

F3 · price: No consideration was received for the shares, which were transferred by gift to relatives.

SEC source: 0001133416-24-000060 · form4.xml · nonDerivative · entry 1

ELDRED KARY · CIK 0001543425 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,213

SEC source: 0001133416-24-000058 · form4.xml · nonDerivative · entry 1

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,769

SEC source: 0001133416-24-000056 · form4.xml · nonDerivative · entry 2

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By a limited liability company controlled by the Reporting Person: Freeman Global Holdings LLC

Disclosed balance after: 80,000

F1 · ownership.nature: Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001133416-24-000056 · form4.xml · nonDerivative · entry 1

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,469

SEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 6

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 747,016

F1 · kind: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend.

F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9.

F1 · price: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend.

SEC source: 0001133416-24-000054 · form4.xml · nonDerivative · entry 3

Zordani Richard A. Jr. · CIK 0001827180 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,083

SEC source: 0001133416-24-000054 · form4.xml · nonDerivative · entry 1

Zordani Richard A. Jr. · CIK 0001827180 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · as UTMA custodian for a minor child

Disclosed balance after: 2,000

F1 · ownership.nature: These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.

SEC source: 0001133416-24-000054 · form4.xml · nonDerivative · entry 2

Zordani Richard A. Jr. · CIK 0001827180 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,324

SEC source: 0001133416-24-000052 · form4.xml · derivative · entry 2

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.

SEC source: 0001133416-24-000052 · form4.xml · derivative · entry 1

Jamil Khurram · CIK 0002032345 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2034-08-01

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest as follows: 25% on each of October 31, 2024; January 31, 2025; April 30, 2025; and July 31, 2025.

SEC source: 0001133416-24-000048 · form4.xml · nonDerivative · entry 1

ELDRED KARY · CIK 0001543425 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,713

SEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 7

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 746,416

F3 · price: No consideration was received for the shares, which were transferred by gift to relatives.

SEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 5

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 746,016

F3 · price: No consideration was received for the shares, which were transferred by gift to relatives.

SEC source: 0001133416-24-000044 · form4.xml · nonDerivative · entry 1

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,469

SEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 4

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 750,416

F3 · price: No consideration was received for the shares, which were transferred by gift to relatives.

SEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 3

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 754,816

F3 · price: No consideration was received for the shares, which were transferred by gift to relatives.

SEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 2

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 759,216

F3 · price: No consideration was received for the shares, which were transferred by gift to relatives.

SEC source: 0001133416-24-000042 · form4.xml · nonDerivative · entry 1

Zordani Richard A. Jr. · CIK 0001827180 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · as UTMA custodian for a minor child

Disclosed balance after: 1,000

F1 · ownership.nature: These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.

SEC source: 0001133416-24-000040 · form4.xml · nonDerivative · entry 1

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · as UTMA custodian for a minor child

Disclosed balance after: 2,000

F1 · shares: Represents average price in multiple transactions with low of $3.30 per share and high of $3.41 per share

F1 · price: Represents average price in multiple transactions with low of $3.30 per share and high of $3.41 per share

F2 · ownership.nature: These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.

SEC source: 0001493152-24-015877 · ownership.xml · nonDerivative · entry 2

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By 10X Fund, LP

Disclosed balance after: 5,922,207

F1 · ownership.direct: The securities were sold by 10X Fund, LP. James C. Czirr is the manager of 10X Capital Management, LLC, which is the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such Mr. Czirr may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001493152-25-017839 · ownership.xml · nonDerivative · entry 2

10X Fund, L.P. · CIK 0001453356 · 10% owner

10X Capital Management, LLC · CIK 0001457247 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 10X Fund, LP

Disclosed balance after: 5,922,207

F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

SEC source: 0001133416-24-000038 · form4.xml · nonDerivative · entry 1

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,969

SEC source: 0001493152-24-015877 · ownership.xml · nonDerivative · entry 1

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By 10X Fund, LP

Disclosed balance after: 5,925,884

F1 · ownership.direct: The securities were sold by 10X Fund, LP. James C. Czirr is the manager of 10X Capital Management, LLC, which is the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such Mr. Czirr may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001493152-25-017839 · ownership.xml · nonDerivative · entry 1

10X Fund, L.P. · CIK 0001453356 · 10% owner

10X Capital Management, LLC · CIK 0001457247 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By 10X Fund, LP

Disclosed balance after: 5,925,884

F1 · ownership.direct: 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

SEC source: 0001133416-24-000036 · form4.xml · nonDerivative · entry 1

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · IRA

Disclosed balance after: 18,063

SEC source: 0001641172-25-014742 · ownership.xml · nonDerivative · entry 1

CZIRR JAMES C · CIK 0001260641 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 763,616

F1 · kind: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend.

F2 · kind: Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9.

F1 · price: Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend.

SEC source: 0001133416-24-000032 · form4.xml · nonDerivative · entry 1

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 897,716

F1 · security: Mr. Lewis and Galectin Therapeutics Inc. entered into an employment agreement, dated August 31, 2020, and a Deferred Stock Unit Agreement, dated August 31, 2020, amended on July 25, 2022. Pursuant to these agreements, 80% of Mr. Lewis' compensation will be paid in the form of deferred stock units ("DSUs") in accordance with the terms and subject to the provisions set forth in the Deferred Stock Unit Agreement. The shares of Common Stock being reported herein underly DSUs issued to Mr. Lewis pursuant to the agreements, at a price per share equal to the closing price of the Common Stock on date of the transaction. The DSUs shall be settled in shares of Common Stock as follows: (i) twenty five percent shall be settled on March 1, 2023, (ii) twenty five percent shall be settled on September 1, 2028 and (iii) fifty percent shall be settled on March 1, 2024.

F3 · shares: Represents shares withheld from issuance to Mr. Lewis for federal and state withholding taxes on income.

F2 · balance_after: Represents shares underlying DSUs and Common Stock.

SEC source: 0001133416-24-000012 · form4.xml · derivative · entry 1

CARSON BENJAMIN SR · CIK 0000017940 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-01-24

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2024.

SEC source: 0001133416-24-000028 · form4.xml · derivative · entry 1

Zordani Richard A. Jr. · CIK 0001827180 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-01-24

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2024.

SEC source: 0001133416-24-000026 · form4.xml · derivative · entry 3

Uihlein Richard E · CIK 0001694903 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-01-24

F3 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F4 · derivative.exercise_date: The options vest 100% on December 31, 2024.

SEC source: 0001133416-24-000026 · form4.xml · nonDerivative · entry 1

Uihlein Richard E · CIK 0001694903 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,268,751

F1 · shares: These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2024. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2024.

SEC source: 0001133416-24-000024 · form4.xml · derivative · entry 1

Schwartz Elissa J. · CIK 0001827177 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-01-24

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2024.

SEC source: 0001133416-24-000022 · form4.xml · derivative · entry 1

Rubin Marc · CIK 0001412377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-01-24

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2024.

SEC source: 0001133416-24-000020 · form4.xml · derivative · entry 1

OMENN GILBERT S · CIK 0001184227 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-01-24

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2024.

SEC source: 0001133416-24-000018 · form4.xml · derivative · entry 2

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,000

Underlying: Common Stock · 56,000 shares

Expires not disclosed

F3 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

F4 · derivative.exercise_date: Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.

F4 · derivative.expiration_date: Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.

SEC source: 0001133416-24-000018 · form4.xml · derivative · entry 1

LEWIS JOEL · CIK 0001725595 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,000

Underlying: Common Stock · 91,000 shares

Expires 2034-01-24

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2024; December 31, 2024; June 30, 2025; and December 31, 2025.

SEC source: 0001133416-24-000016 · form4.xml · derivative · entry 1

FREEMAN KEVIN D · CIK 0001522478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-01-24

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2024.

SEC source: 0001133416-24-000014 · form4.xml · derivative · entry 1

ELDRED KARY · CIK 0001543425 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2034-01-24

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest 100% on December 31, 2024.

SEC source: 0001133416-24-000010 · form4.xml · derivative · entry 2

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires not disclosed

F4 · derivative.exercise_price: The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.

SEC source: 0001133416-24-000010 · form4.xml · derivative · entry 1

CALLICUTT JACK W · CIK 0001266773 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-01-24

F1 · security: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

F2 · derivative.exercise_date: The options vest as follows: 25% on each of June 30, 2024; December 31, 2024; June 30, 2025; and December 31, 2025.